New therapeutic approaches to sickle cell disease;Essais cliniques de nouvelles thérapeutiques pharmacologiques de la drépanocytose

Cahiers Sante

Volumn 16, Issue 4, 2006, Pages 263-268

  Brugnara, Carlo ^a   De Franceschi, Lucia ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Sickle cell disease; Therapeutic study and trials; Therapeutics

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; ACETAMIDE DERIVATIVE; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTITHROMBOCYTIC AGENT; ARGININE; CLOTRIMAZOLE; COTRANSPORTER; DIPYRIDAMOLE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, HUMAN; NITRIC OXIDE; POTASSIUM CHLORIDE SYMPORTERS; POTASSIUM-CHLORIDE SYMPORTERS; PYROGLUTAMIC ACID; TRITYL DERIVATIVE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL; ARTICLE; CELL ADHESION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; HUMAN; ISCHEMIA; MOUSE; PATHOPHYSIOLOGY; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

ACETAMIDES; ANEMIA, SICKLE CELL; ANIMALS; ARGININE; CELL ADHESION; CLINICAL TRIALS; CLOTRIMAZOLE; DIPYRIDAMOLE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ERYTHROCYTE AGGREGATION; ERYTHROCYTES; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; ISCHEMIA; MEMBRANE TRANSPORT MODULATORS; MICE; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; PYRROLIDONECARBOXYLIC ACID; SYMPORTERS; TRITYL COMPOUNDS; VASODILATOR AGENTS;

EID: 34248331652     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: 10.1684/san.2007.0045     Document Type: Article

References (32)

1. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem 1990 ; 40 : 63-279.
2. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999 ; 340 : 1021-30.
3. Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992 ; 79 : 2154-63.
4. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease : a pilot study. Blood 2001 ; 97 : 1937-41.
5. Hebbel RP Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997 ; 100:583-886.
6. Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998 ; 91 : 304451.
7. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995 ; 332 : 1317-22.
8. De Franceschi L, Corroche R. Established and experimental treatments for sickle cell disease. Haematologica 2004 ; 89 : 348-56.
9. Fabry ME, Nagel RL. Heterogeneity of red cells in the sickler : a characteristic with practical clinical and pathophysiological implications. Blood Cells 1982 ; 8 : 9-15.
10. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997 ; 100 : 1847-52.
11. Brugnara C, de Franceschi L, Alper SL. Inhibition of Ca(2+)dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin In vest 1993 ; 92 : 520-6.
12. Bennekou P, de Franceschi L, Pedersen O, et al. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice : a possible new therapeutic approach for sickle cell disease. Blood 2001 ; 97 : 1451-7.
13. Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997 ; 99 : 2727-35.
14. McGoron AJ, Joiner CH, Palascak MB, Claussen WJ, Franco RS. Dehydration of mature and immature sickle red blood cells during fast oxygenation/ deoxygenation cycles : role of KCl cotransport and extracellular calcium. Blood 2000 ; 95 : 2164-8.
15. Franco RS, Thompson H, Palascak M, Joiner CH. The formation of transferrin receptorpositive sickle reticulocytes with intermediate density is not determined by fetal hemoglobin content. Blood 1997; 90 : 3195-203.
16. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958 ; 30 : 653-4.
17. Stocker JW, De Franceschi L, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003 ; 101 : 2412-8.
18. Ataga Kl, DeCastro LM, Swerdlow P, Saunthararajay Y, Smith W. Efficacy and safety of the Gardos channel inhibitor, ICA-17043, in patients with sickle cell anemia. Blood 2004 ; 104 : 33a.
19. Orringer EP, Casella JF, Ataga Kl, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease : A randomized controlled trial. JAMA 2001 ; 286 : 2099-106.
20. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000 ; 95 : 368-74.
21. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood 1999 ; 93 : 1422-9.
22. Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 2004; 103: 2397-400.
23. Gupta N, Ahmed I, Nissel-Horowitz S, Patel D, Mehrotra B. Intravenous gammaglobulin-associated acute renal failure. Am J Hematol 2001 ; 66 : 151-2.
24. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion : case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000 ; 75 : 83-5.
25. Caress JB, Cartwright MS, Donofrio PD, Peacock Jr. JE. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 2003 ; 60 : 1822-4.
26. Kaul DK, Liu X, Nagel RL. Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature. Blood 2001 ; 98 : 3128-31.
27. Lopez BL, Kreshak AA, Morris CR, DavisMoon L, Ballas SK, Ma XL. L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003 ; 120 : 532-4.
28. Girgis RE, Qureshi MA, Abrams J, Swerdlow P. Decreased exhaled nitric oxide in sickle cell disease : relationship with chronic lung involvement. Am J Hematol 2003 ; 72 : 177-84.
29. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vasoocclusive crisis in pediatric patients with sickle cell disease. JAMA 2003 ; 289 : 1136-42.
30. de Franceschi L, Baron A, Scarpa A, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell diseasespecific lung injury induced by hypoxia/reoxygenation. Blood 2003 ; 102 : 1087-96.
31. Morris CR, Morris Jr. SM, Hagar W, et al. Arginine therapy : a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003 ; 168 : 63-9.
32. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysisassociated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005 ; 294 : 81-90.